Burden of Upper Gastrointestinal Symptoms in Patients Receiving Low-Dose Acetylsalicylic Acid for Cardiovascular Risk Management
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Continuous low-dose acetylsalicylic acid (aspirin; ASA) is a mainstay of cardiovascular (CV) risk management. It is well established, however, that troublesome upper gastrointestinal (GI) symptoms are commonly experienced among low-dose ASA users.
The objective of this study was to investigate the occurrence of upper GI symptoms, and their impact on well-being, among patients taking low-dose ASA for CV risk management.
This was a multicenter, non-interventional, 12-week study carried out in primary-care, cardiology, and practice group centers in the USA, Canada, and France.
Eligible patients were adults (age ≥18 years) at risk of or with confirmed CV disease, with physician-prescribed/-recommended low-dose ASA (75–325 mg) use.
Main Outcome Measures
An electronic device (eDiary) was used to collect patient-reported outcome data three times per day (morning, afternoon, and evening; regular reports), including upper GI (gastroesophageal disease [GERD]-like or dyspepsia-like) symptoms and the impact of such symptoms on sleep quality, perceived stress, and emotions. In addition to regular reports, patients were able to self-initiate a report of upper GI symptoms (spontaneous reports).
Overall, 81,282 eDiary reports (including 4,407 spontaneous reports of upper GI symptoms) were collected from 340 patients. Upper GI symptoms (most commonly GERD-like) were commonly blamed on food/drink (39 %), and around one-third of patients (37 %) used medication to relieve their symptoms. Analysis showed that upper GI symptoms had a negative impact on sleep quality, perceived stress, and emotions (all p < 0.01). Overall, GI medication use was infrequent, but was more common among low-dose ASA-experienced patients (41 % vs. 12 % of evening reports in patients naïve to low-dose ASA at baseline; p < 0.01); adherence to prescribed daily proton pump inhibitors (PPIs) was poor (47 %).
Upper GI symptoms impact negatively on well-being among low-dose ASA users, in terms of decreased quality of sleep, increases in perceived stress, and negative impact on emotions. Despite this, patients may not necessarily associate these symptoms with their low-dose ASA therapy and do not readily take steps to manage such symptoms, which extends to poor adherence to prescribed daily PPIs.
- Baigent, C, Blackwell, L, Collins, R (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373: pp. 1849-1860 CrossRef
- Patrono, C, Bachmann, F, Baigent, C (2004) Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 25: pp. 166-181 CrossRef
- Biondi-Zoccai, GG, Lotrionte, M, Agostoni, P (2006) A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 27: pp. 2667-2674 CrossRef
- Burger, W, Chemnitius, JM, Kneissl, GD (2005) Low-dose aspirin for secondary cardiovascular prevention—cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation—review and meta-analysis. J Intern Med 257: pp. 399-414 CrossRef
- Maulaz, AB, Bezerra, DC, Michel, P (2005) Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol 62: pp. 1217-1220 CrossRef
- Tuppin, P, Neumann, A, Danchin, N (2010) Evidence-based pharmacotherapy after myocardial infarction in France: adherence-associated factors and relationship with 30-month mortality and rehospitalization. Arch Cardiovasc Dis 103: pp. 363-375 CrossRef
- Collet, JP, Montalescot, G, Blanchet, B (2004) Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation 110: pp. 2361-2367 CrossRef
- Ferrari, E, Benhamou, M, Cerboni, P (2005) Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol 45: pp. 456-459 CrossRef
- Eisenberg, MJ, Richard, PR, Libersan, D (2009) Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. Circulation 119: pp. 1634-1642 CrossRef
- Lanas, A, Scheiman, J (2007) Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin 23: pp. 163-173 CrossRef
- Laine, L (2001) Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 120: pp. 594-606 CrossRef
- Serrano, P, Lanas, A, Arroyo, MT (2002) Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther 16: pp. 1945-1953 CrossRef
- Taha, AS, Angerson, WJ, Prasad, R (2008) Clinical trial: the incidence and early mortality after peptic ulcer perforation, and the use of low-dose aspirin and nonsteroidal anti-inflammatory drugs. Aliment Pharmacol Ther 28: pp. 878-885
- Yeomans, ND, Lanas, AI, Talley, NJ (2005) Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 22: pp. 795-801 CrossRef
- Camilleri, M, Dubois, D, Coulie, B (2005) Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol 3: pp. 543-552 CrossRef
- Nandurkar, S, Talley, NJ, Xia, H (1998) Dyspepsia in the community is linked to smoking and aspirin use but not to Helicobacter pylori infection. Arch Intern Med 158: pp. 1427-1433 CrossRef
- Heading, RC (1999) Prevalence of upper gastrointestinal symptoms in the general population: a systematic review. Scand J Gastroenterol 231: pp. 3-8
- Whitaker, MJ, Brun, J, Carelli, F (1997) Controversy and consensus in the management of upper gastrointestinal disease in primary care. The International Gastro Primary Care Group. Int J Clin Pract 51: pp. 239-243
- Pratt, S, Thompson, VJ, Elkin, EP (2010) The impact of upper gastrointestinal symptoms on nonadherence to, and discontinuation of, low-dose acetylsalicylic acid in patients with cardiovascular risk. Am J Cardiovasc Drugs 10: pp. 281-288 CrossRef
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348: pp. 1329-1339 CrossRef
- Bytzer, P (2010) Dyspepsia as an adverse effect of drugs. Best Pract Res Clin Gastroenterol 24: pp. 109-120 CrossRef
- Cayla, G, Collet, JP, Silvain, J (2012) Prevalence and clinical impact of upper gastrointestinal symptoms in subjects treated with low dose aspirin: the UGLA survey. Int J Cardiol 156: pp. 69-75 CrossRef
- Bommel, MJ, Numans, ME, Wit, NJ (2001) Consultations and referrals for dyspepsia in general practice - a one year database survey. Postgrad Med J 77: pp. 514-518 CrossRef
- Broker, LE, Hurenkamp, GJ, Riet, G (2009) Upper gastrointestinal symptoms, psychosocial co-morbidity and health care seeking in general practice: population based case control study. BMC Fam Pract 10: pp. 63 CrossRef
- Krystal, AD, Walsh, JK, Laska, E (2003) Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 26: pp. 793-799
- Roth, T, Walsh, JK, Krystal, A (2005) An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 6: pp. 487-495 CrossRef
- Scharf, M, Erman, M, Rosenberg, R (2005) A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep 28: pp. 720-727
- Zammit, GK, McNabb, LJ, Caron, J (2004) Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 20: pp. 1979-1991 CrossRef
- Shiffman, S, Paty, JA, Gnys, M (1996) First lapses to smoking: within-subjects analysis of real-time reports. J Consult Clin Psychol 64: pp. 366-379 CrossRef
- Palermo, TM, Valenzuela, D, Stork, PP (2004) A randomized trial of electronic versus paper pain diaries in children: impact on compliance, accuracy, and acceptability. Pain 107: pp. 213-219 CrossRef
- Cates C, Roberts L, Eremenco S, et al. Can older, chronically ill adults use electronic diaries? Compliance rates in a prospective study of COPD [abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Orlando; 2009.
- Reed D, Curry C, Rocchio S, et al. COPD eDiary compliance: comparison of age, symptom score, duration in clinical trial and country of origin [abstract]. European Respiratory Society (ERS), Barcelona; 2010.
- Stone, AA, Broderick, JE, Schwartz, JE (2003) Intensive momentary reporting of pain with an electronic diary: reactivity, compliance, and patient satisfaction. Pain 104: pp. 343-351 CrossRef
- Herlitz, J, Tóth, PP, Næsdal, J (2010) Low-dose acetylsalicylic acid therapy for CV prevention: quantification and consequences of poor compliance or discontinuation. Am J Cardiovasc Drugs 10: pp. 125-141 CrossRef
- Yeomans, N, Lanas, A, Labenz, J (2008) Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol 103: pp. 2465-2473 CrossRef
- Muller, P, Simon, B (1998) The action of the proton pump inhibitor pantoprazol against acetylsalicylic acid-induced gastroduodenopathy in comparison to ranitidine. An endoscopic controlled, double blind comparison [in German]. Arzneimittelforschung 48: pp. 482-485
- Scheiman, JM, Devereaux, PJ, Herlitz, J (2011) Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart 97: pp. 797-802 CrossRef
- Lanas, A, Rodrigo, L, Marquez, JL (2003) Low frequency of upper gastrointestinal complications in a cohort of high-risk patients taking low-dose aspirin or NSAIDS and omeprazole. Scand J Gastroenterol 38: pp. 693-700 CrossRef
- Lai, KC, Lam, SK, Chu, KM (2002) Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 346: pp. 2033-2038 CrossRef
- Laheij, RJ, Rossum, LG, Jansen, JB (2003) Proton-pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: a randomized placebo-controlled trial. Aliment Pharmacol Ther 18: pp. 109-115 CrossRef
- Quittner, AL, Modi, AC, Lemanek, KL (2008) Evidence-based assessment of adherence to medical treatments in pediatric psychology. J Pediatr Psychol 33: pp. 916-936 CrossRef
- Margolis, MK, Halling, K, Sörstadius, E (2009) Upper gastrointestinal symptoms experienced by users of low-dose aspirin (acetylsalicylic acid) [75–325 mg/day] for primary and secondary coronary artery disease prevention: perspectives from patient focus groups. Patient 2: pp. 89-93 CrossRef
- Burden of Upper Gastrointestinal Symptoms in Patients Receiving Low-Dose Acetylsalicylic Acid for Cardiovascular Risk Management
American Journal of Cardiovascular Drugs
Volume 13, Issue 1 , pp 27-35
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing AG
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Department of Gastroenterology, Køge University Hospital, Copenhagen University, Lykkebækvej 1, 4600, Køge, Denmark
- 2. Harmony Clinical Research, San Ramon, CA, USA
- 3. ICON Clinical Research, San Francisco, CA, USA
- 4. AstraZeneca R&D, Mölndal, Sweden